VivoSeq
Cardiovascular

Venous Leg Ulcer

1

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Venous Leg Ulcer is an early-stage landscape with 1 program across 1 company. The most active players are NuScience Medical Biologics, LLC.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

NuScience Medical Biologics, LLC

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

XSTEM-VLU

Xintela AB

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

5

clinical trials

Unknown status2 · 40%
Terminated1 · 20%
Recruiting1 · 20%
Completed1 · 20%

Clinical Trials

Trial Activity

Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer
Unknown status·HHealthpoint·N/A·NCT01658618·440 enrolled
Amniotic Membrane Allograft Application in the Management of Venous Leg Ulcerations
Terminated·PPrisma Health-Upstate·Phase 4·NCT02929056·2 enrolled
A Study to Evaluate ENERGI-F703 GEL in Venous Leg Ulcer
Unknown status·EEnergenesis Biomedical Co., Ltd.·Phase 2·NCT04078555·80 enrolled
Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg Ulcers: A Randomized Controlled Multicenter Crossover Trial
Recruiting·NNuScience Medical Biologics, LLC·Preclinical·NCT07335861·122 enrolled
A Multi-centre, Randomised, Single-blind Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of a Single Topical Dose of Allogeneic Integrin α10β1-selected Mesenchymal Stem Cells (XSTEM-VLU) in Patients With Difficult-to-heal Venous Leg Ulcers
Completed·XXintela AB·Preclinical·NCT05549609·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)